Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.59 |
| ▸ | RAB9A | P51151 | 3/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.59 |
| ▸ | RELA | Q04206 | 1/20 | 0.59 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AHR | P35869 | 2/20 | 0.46 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28135259 | 0.97 | NPC1 (0.63) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6685962 | 0.86 | CLK4 (0.64) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| Bromobenzene SCHEMBL28286547 | 0.85 | NPC1 (0.61) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL16625771 | 0.83 | CLK4 (0.61) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27655232 | 0.83 | NPC1 (0.53) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL27641903 | 0.81 | RAB9A (0.61) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL16222829 | 0.79 | NPC1 (0.65) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL28135372 | 0.78 | BIRC5 (0.50) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6048308 | 0.77 | NPC1 (0.52) | NPC1RAB9ASMN1; SMN2NFKB1NFKB2 | |
| SCHEMBL6362896 | 0.77 | MEN1 (0.82) | NPC1RAB9ASMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 115 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108148055-A | A kind of D- π-A types organic fluorescence materials and preparation method based on naphthalene | 陕西师范大学 | 2018-06-12 | — | — | CN | claimed |
| EP-3814355-B1 | TRIAZOLOTRIAZINE DERIVATIVES AS A2A RECEPTOR ANTAGONISTS | ZHEJIANG VIMGREEN PHARMACEUTICALS LTD (CN) | 2025-12-24 | — | — | EP | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-117890340-A | Application of 9, 10-dihydroacridine derivative in gas-phase detection of ice toxin or ice toxin mimic N-methamphetamine | 吉林大学 | 2024-04-16 | — | — | CN | disclosed |
| EP-3790867-B1 | KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE | IMAGO BIOSCIENCES INC (US) | 2024-03-27 | — | — | EP | disclosed |
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | IMAGO BIOSCIENCES, INC. (US) | 2024-03-19 | — | — | US | disclosed |
| CN-112513020-B | KDM1A inhibitors for the treatment of diseases | 伊美格生物科学公司 | 2024-02-23 | — | — | CN | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ZHEJIANG VIMGREEN PHARMACEUTICALS, LTD. (CN) | 2024-01-02 | — | — | US | disclosed |
| US-5627184-A | BACTERICIDES OF PYRIMIDINE DERIVATIVES | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-05-06 | — | — | US | disclosed |
| US-5606058-A | HAVING REDUCED SIDE EFFECTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1997-02-25 | — | — | US | disclosed |
| WO-1996040114-A1 | METHODS OF INHIBITING PNEUMOCYSTIS CARINII PNEUMONIA AND COMPOUNDS USEFUL THEREFOR | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040117-A1 | METHODS OF TREATING MICROBIAL INFECTIONS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1996-12-19 | — | — | WO | disclosed |
| EP-0725067-A1 | Substituted biphenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-08-07 | — | — | EP | disclosed |
| US-5521189-A | PYRIMIDINE COMPOUNDS AS ANTIPROTOZOA AGENTS | THE UNIVERSITY OF NC AT CH (US) | 1996-05-28 | — | — | US | disclosed |
| US-4533505-A | REACTION OF ETHYLENE IWITH ACID HALIDES IN THE PRESENCE OF A BASE AND A PALLADIUM CATALYST | CIBA-GEIGY CORPORATION (US) | 1985-08-06 | — | — | US | disclosed |
| EP-0062005-B1 | PROCESS FOR THE MANUFACTURE OF STYRENE AND/OR STILBENE DERIVATIVES | CIBA-GEIGY AG (CH) | 1985-06-26 | — | — | EP | disclosed |
| US-4335055-A | Process for the preparation of alkenylbenzene derivatives or alkenylnaphthalene derivatives | CIBA-GEIGY CORPORATION (US) | 1982-06-15 | — | — | US | disclosed |
| EP-0041043-A1 | Process for the preparation of derivatives of alkenyl benzene or alkenyl naphthalene | CIBA-GEIGY AG (CH) | 1981-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11932629-B2 | KDM1A inhibitors for the treatment of disease | KDM1B, KDM1A, KDM2A | NPC1 4463/4885RAB9A 3444/4885SMN1; SMN2 835/4885 |
| US-11858942-B2 | Triazolotriazine derivatives as A2A receptor antagonists | ADORA2A, ADORA1, ADORA3 | NPC1 1520/4885RAB9A 2869/4885SMN1; SMN2 4178/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | NPC1 4533/4885RAB9A 893/4885SMN1; SMN2 4155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.